VEGF-B Inhibitors is a rapidly growing segment within the broader oncology and drug development landscape, driven by the increasing recognition of vascular endothelial growth factor-C (VEGF-C) as a key factor in the development of lymphatic vessels and the progression of various cancers. VEGF-C plays a critical role in the lymphangiogenesis process, contributing to tumor growth, metastasis, and resistance to therapies. As such, VEGF-C inhibitors are being explored as a promising therapeutic approach for treating cancers like breast cancer, melanoma, and non-small cell lung cancer (NSCLC), where lymphatic spread is a significant concern.
